Skip to main content
SpringerLink
Log in

Clinical tools for successful treatment of onychomycosis: a narrative review

  • Review Article
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Onychomycosis is a difficult-to-treat fungal infection of the human nail plate or bed that primarily affects the natural anatomy of human toe and finger nails, leading to a hard, brittle, and uneven nail surface. The severe structural mutilation of nails restricts the application of conventional formulations and makes onychomycosis therapy a challenging clinical premise. Oral therapy with drugs such as terbinafine hydrochloride and itraconazole may lead to drug interactions and systemic adverse effects, whereas topical treatment with drugs such as ciclopirox olamine and amorolfine are often associated with poor drug permeation through the nail bed. Recent advances in laser/photodynamic therapies and their application in onychomycosis has emerged as a new therapeutic paradigm with global acceptance. The present article is an attempt to provide an insight into onychomycosis and its manifestations, and summarises the various therapeutic modalities, with a greater focus on laser/photodynamic therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

(photo courtesy of Wikipedia; the copyright holder has granted permission for the work to be copied, distributed, and/or modified under the terms of the GNU Free Documentation License, Version 1.2)

Similar content being viewed by others

References

  1. Kozarev J, Vizintin Z. Novel laser therapy in treatment of onychomycosis. J Laser Health Acad. 2010;1(1):1–8.

    Google Scholar 

  2. Ibrahim SA, Albalat W, Ebrahim HM. Evaluation of long pulsed Nd-YAG laser in the treatment of onychomycosis. J Cosmet Laser Ther. 2019;21(2):76–81.

    PubMed  Google Scholar 

  3. Baran R, Gupta AK, Piérard GE. Pharmacotherapy of onychomycosis. Expert Opin Pharmacother. 2005;6(4):609–24.

    CAS  PubMed  Google Scholar 

  4. Evans EG. Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol. 1998;38(5):S32–6.

    CAS  PubMed  Google Scholar 

  5. Zaias N, Glick B, Rebell G. Diagnosing and treating onychomycosis. J Fam Pract. 1996;42(5):513–9.

    CAS  PubMed  Google Scholar 

  6. Kaur R, Kashyap B, Bhalla P. Onychomycosis-epidemiology, diagnosis and management. Indian J Med Microbiol. 2008;26(2):108.

    CAS  PubMed  Google Scholar 

  7. Elewski BE. Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev. 1998;11(3):415–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Westerberg DP, Voyack MJ. Onychomycosis: current trends in diagnosis and treatment. Am Fam Physician. 2013;88(11):762–70.

    PubMed  Google Scholar 

  9. Piraccini BM, Lorenzi S, Tosti A. ‘Deep’ white superficial onychomycosis due to molds. J Eur Acad Dermatol Venereol. 2002;16(5):532–3.

    CAS  PubMed  Google Scholar 

  10. Piraccini BM, Tosti A. White superficial onychomycosis: epidemiological, clinical, and pathological study of 79 patients. Arch Dermatol. 2004;140(6):696–701.

    PubMed  Google Scholar 

  11. Tosti A, Baran R, Piraccini BM, et al. “Endonyx” onychomycosis: a new modality of nail invasion by dermatophytes. Acta Derm Venereol. 1999;79:52–3.

    CAS  PubMed  Google Scholar 

  12. Singal A, Khanna D. Onychomycosis: diagnosis and management. Indian J Dermatol Venerol. 2011;77(6):659.

    Google Scholar 

  13. Wilsmann-Theis D, Sareika F, Bieber T, et al. New reasons for histopathological nail-clipping examination in the diagnosis of onychomycosis. J Eur Acad Dermatol Venereol. 2011;25(2):235–7.

    CAS  PubMed  Google Scholar 

  14. Katz HI. Drug interactions of the newer oral antifungal agents. Br J Dermatol. 1999;141:26–32.

    PubMed  Google Scholar 

  15. Hall M, Monka C, Krupp P, et al. Safety of oral terbinafine: results of a post marketing surveillance study in 25 884 patients. Arch Dermatol. 1997;133(10):1213–9.

    CAS  PubMed  Google Scholar 

  16. Dembskey N, Abrahamse H. Laser therapy for the treatment of onychomycosis: best evidence based practice or not. Clin Res Foot Ankle. 2016;4(211):2.

    Google Scholar 

  17. Iorizzo M, Piraccini BM, Rech G, et al. Treatment of onychomycosis with oral antifungal agents. Expert Opin Drug Deliv. 2005;2(3):435–40.

    PubMed  Google Scholar 

  18. Shirwaikar AA, Thomas T, Shirwaikar A, et al. Treatment of onychomycosis: an update. Indian J Pharm Sci. 2008;70(6):710.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Del Rosso JQ. The role of topical antifungal therapy for onychomycosis and the emergence of newer agents. J Cosmet Dermatol. 2014;7(7):10.

    Google Scholar 

  20. Gupta AK, Schouten JR, Lynch LE. Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective. Skin Ther Newsl. 2005;10(7):1–3.

    CAS  Google Scholar 

  21. Firoz S, Sirisha MN, Rajalakshmi R. Transungual drug delivery system: a review. Int J Innov Drug Discov. 2011;1:9–14.

    Google Scholar 

  22. Hussan D, Choudhary SR, Sharma D, et al. Transungual drug delivery: a novel approach of unique features. Indo Am J Pharm Res. 2013;3(6):4460–70.

    Google Scholar 

  23. Akhtar N, Sharma H, Pathak K. Onychomycosis: potential of nail lacquers in transungual delivery of antifungals. Scientifica (Cairo). 2016;2016:1387936

    PubMed  PubMed Central  Google Scholar 

  24. Hasan N, Singh M, Sulaiman S, et al. Design, development and optimization of a transungual duple nail lacquer for onychomycosis therapy. J Eur Acad Dermatol Venereol. 2018;32(6):e250–1.

    CAS  PubMed  Google Scholar 

  25. Hassan N, Singh M, Sulaiman S, et al. Molecular docking-guided ungual drug-delivery design for amelioration of onychomycosis. ACS Omega. 2019;4(5):9583–92.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Bhatta AK, Huang X, Keyal U, et al. Laser treatment for onychomycosis: a review. Mycoses. 2014;57(12):734–40.

    PubMed  Google Scholar 

  27. Kim YR, Lee YW, Choe YB, et al. Lack of antifungal effect of 1064-nm long pulse Nd:YAG laser on the growth of Trichophyton rubrum. Lasers Med Sci. 2015;30(6):1811–3.

    PubMed  Google Scholar 

  28. Bhatta AK, Keyal U, Wang X, et al. A review of the mechanism of action of lasers and photodynamic therapy for onychomycosis. Lasers Med Sci. 2017;32(2):469–77.

    PubMed  Google Scholar 

  29. Vural E, Winfield HL, Shingleton AW, et al. The effects of laser irradiation on Trichophyton rubrum growth. Lasers Med Sci. 2008;23(4):349–53.

    PubMed  Google Scholar 

  30. Kozarev J, Mitrovica S. Laser treatment of nail fungal infection [poster]. In: Proceedings of the Berlin conference of the european academy of dermatology and venereology; 2009. http://www.centrosbys.com/descargas/86782_clinical_bulletin_10_01_1_0_eadv_onychomycosis_kozarev.pdf

  31. Hees H, Raulin C, Bäumler W. Laser treatment of onychomycosis: an in vitro pilot study. J Dtsch Dermatol Ges. 2012;10(12):913–7.

    PubMed  Google Scholar 

  32. Gupta A, Simpson F. Device-based therapies for onychomycosis treatment. Skin Ther Lett. 2012;17(9):4–9.

    CAS  Google Scholar 

  33. Zhang RN, Wang DK, Zhuo FL, et al. Long-pulse Nd:YAG 1064-nm laser treatment for onychomycosis. Chin Med J (Engl). 2012;125(18):3288–91.

    PubMed  Google Scholar 

  34. Kim MS, Jung JY, Cho EB, et al. The effectiveness of 1,064-nm long-pulsed Nd:YAG laser in the treatment of severe onychomycosis. J Cosmet Laser Ther. 2016;18(6):317–22.

    PubMed  Google Scholar 

  35. Moon SH, Hur H, Oh YJ, et al. Treatment of onychomycosis with a 1,064-nm long-pulsed Nd:YAG laser. J Cosmet Laser Ther. 2014;16(4):165–70.

    PubMed  Google Scholar 

  36. Li Y, Yu S, Xu J, et al. Comparison of the efficacy of long-pulsed Nd:YAG laser intervention for treatment of onychomycosis of toenails or fingernails. J Drugs Dermatol. 2014;13(10):1258–63.

    PubMed  Google Scholar 

  37. El-Tatawy RA, Abd El-Naby NM, El-Hawary EE, et al. A comparative clinical and mycological study of Nd-YAG laser versus topical terbinafine in the treatment of onychomycosis. J. Dermatol Treat. 2015;26(5):461–4.

    Google Scholar 

  38. Okan G, Tarikci N, Gokdemir G. The effect of long-pulsed Nd:YAG laser for the treatment of onychomycosis. J Am Podiatr Med Assoc. 2017;107(1):54–9.

    PubMed  Google Scholar 

  39. Horine CDP, Dow H, Cozzarelli JDP. Evaluation of a short pulse Nd:YAG laser procedure for infected nails: a retrospective international multicenter study of 262 patients. Chico: NuvoLase Inc.; 2015.

    Google Scholar 

  40. Karsai S, Jäger M, Oesterhelt A, et al. Treating onychomycosis with the short-pulsed 1064-nm-Nd:YAG laser: results of a prospective randomized controlled trial. J Eur Acad Dermatol Venereol. 2017;31(1):175–80.

    CAS  PubMed  Google Scholar 

  41. Kalokasidis K, Onder M, Trakatelli MG, et al. The effect of Q-switched Nd:YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo. Dermatol Res Pract. 2013;2013:379725.

    PubMed  PubMed Central  Google Scholar 

  42. Lim EH, Kim HR, Park YO, et al. Toenail onychomycosis treated with a fractional carbon-dioxide laser and topical antifungal cream. J Am Acad Dermatol. 2014;70(5):918–23.

    PubMed  Google Scholar 

  43. Al-Meligi NK, Shaheen MA, Mahmoud MT, et al. Evaluation of the clinical efficacy of fractional CO2 laser combined with topical antifungal in the treatment of onychomycosis using SCIO (Score Clinical Index of Onychomycosis). Egypt J Hosp Med. 2018;72(4):4313–20.

    Google Scholar 

  44. Zhou BR, Yan LU, Permatasari F, et al. The efficacy of fractional carbon dioxide (CO2) laser combined with luliconazole 1% cream for the treatment of onychomycosis: a randomized, controlled trial. Medicine (Baltimore). 2016;95(44):e5141.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Smijs TG, van der Haas RN, Lugtenburg J, et al. Photodynamic treatment of the dermatophyte Trichophyton rubrum and its microconidia with porphyrin photosensitizers. Photochem Photobiol. 2004;80(2):197–202.

    CAS  PubMed  Google Scholar 

  46. Bhatta AK, Keyal U, Huang X, et al. Fractional carbon-dioxide (CO2) laser-assisted topical therapy for the treatment of onychomycosis. J Am Acad Dermatol. 2016;74(5):916–23.

    PubMed  Google Scholar 

  47. Abd El-Aal EB, Abdo HM, Ibrahim SM, et al. Fractional carbon dioxide laser assisted delivery of topical tazarotene versus topical tioconazole in the treatment of onychomycosis. J. Dermatol Treat. 2018;25:1–6.

    Google Scholar 

  48. Manevitch Z, Lev D, Hochberg M, et al. Direct antifungal effect of femtosecond laser on Trichophyton rubrum onychomycosis. J Photochem Photobiol B. 2010;86:476–9.

    CAS  Google Scholar 

  49. Bornstein E, Hermans W, Gridley S, et al. Near-infrared photoinactivation of bacteria and fungi at physiologic temperatures. Photochem Photobiol. 2009;85(6):1364–74.

    CAS  PubMed  Google Scholar 

  50. Sotiriou E, Koussidou-Ermonti T, Chaidemenos G, et al. Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single-centre open trial. Acta Derm Venereol. 2010;90(2):216–7.

    PubMed  Google Scholar 

  51. Tardivo JP, Wainwright M, Baptista M. Small scale trial of photodynamic treatment of onychomycosis in São Paulo. J Photochem Photobiol B. 2015;150:66–8.

    CAS  PubMed  Google Scholar 

  52. Figueiredo Souza LW, Souza SV, Botelho AC. Randomized controlled trial comparing photodynamic therapy based on methylene blue dye and fluconazole for toenail onychomycosis. Dermatol Ther. 2014;27(1):43–7.

    CAS  PubMed  Google Scholar 

  53. Houang J, Perrone GG, Pedrinazzi C, et al. A genome-wide screen for tolerance to rose bengal photodynamic therapy and its use in onychomycosis treatment. San Francisco: SPIE Bios; 2019. https://doi.org/10.1117/12.2509284.

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, 110062, India

    Nazia Hassan, Piyush Dhamija, Vishal Bharti, Sneha Vishwakarma & Zeenat Iqbal

  2. Division of Biochemistry, Faculty of Basic Sciences, SKUAST, Jammu, 180009, India

    Sheikh Mansoor

Authors
  1. Nazia Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Piyush Dhamija
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Vishal Bharti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sneha Vishwakarma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sheikh Mansoor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zeenat Iqbal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors made equal contributions to this review.

Corresponding author

Correspondence to Zeenat Iqbal.

Ethics declarations

Conflict of interest

Nazia Hassan, Piyush Dhamija, Vishal Bharti, Sneha Vishwakarma, Sheikh Mansoor, and Zeenat Iqbal declare they have no conflicts of interest.

Funding

No funding was received for this review.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, N., Dhamija, P., Bharti, V. et al. Clinical tools for successful treatment of onychomycosis: a narrative review. Drugs Ther Perspect 36, 236–242 (2020). https://doi.org/10.1007/s40267-020-00722-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-020-00722-0

Search

Navigation